Please Wait.....
Report
Asia-Pacific Insulin Syringe - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)
Market Report I 2026-02-09 I 70 Pages I Mordor Intelligence
Asia-Pacific Insulin Syringe Market Analysis
Asia-Pacific insulin syringes market size in 2026 is estimated at USD 1.06 billion, growing from 2025 value of USD 1.05 billion with 2031 projections showing USD 1.10 billion, growing at 0.84% CAGR over 2026-2031. Rising diabetes prevalence, expanded reimbursement for pen-averse patients, CGM-guided basal-bolus protocols and safety-engineered innovations underpin demand, while pen-device cannibalization, single-use-plastic legislation and flat pricing temper overall growth. Competitive intensity remains moderate as Becton Dickinson, Novo Nordisk and Terumo defend share against cost-competitive regional players focused on low-dead-space and needlestick-prevention features. Digital pharmacies proliferate across tier-2 and tier-3 cities, mitigating stock-outs and enabling direct-to-patient fulfillment at lower logistics cost. Environmental mandates accelerate R&D into recyclable or biodegradable resin blends, adding compliance costs but fostering premium positioning for eco-conscious brands.
Asia-Pacific Insulin Syringe Market Trends and Insights
Growing Diabetes Prevalence & Insulin-Dependent Patients
Type 1 incidence reached 4.9 cases per 100,000 in India during 2025, while obesity-linked Type 2 keeps rising, sustaining syringe demand even as pens gain favor. Aging cohorts in Japan and Australia require multiple daily injections, and emerging economies expand coverage for newly diagnosed populations, prolonging relevance of traditional syringes. Precision dosing for mixed insulin regimens makes 0.3 mL and 0.5 mL volumes indispensable. Providers favor syringes for complex titration where disposable pens lack fine-scale graduations. Long-term demand thus persists despite low headline growth.
National Reimbursement Expansion for Pen-Averse Patients
China's NVBP cut median insulin prices 42.08%, lowering affordability thresholds from 1.63 to 0.68 days' wage and broadening access to conventional syringes for cost-sensitive users. India and Japan replicate centralized tenders, channeling savings toward pediatric and geriatric cohorts needing flexible dosing. Programs especially benefit gestational diabetes cases requiring temporary therapy. Policy momentum through 2027 supports the Asia-Pacific insulin syringes market by cushioning out-of-pocket costs in low-income groups. Spillover to ASEAN through regional trade pacts amplifies volume upside.
Pen-Device Cannibalization of Syringe Volumes
Domestic Indian makers captured 25% of national insulin revenue by pushing affordable pens that grew 13% YoY in 2025, signaling permanent share shift away from syringes. Japanese endocrinologists now recommend pens as first-line due to dosing accuracy and lower social stigma, suppressing hospital reorder frequencies for 30G syringes. As GLP-1 injectables eclipse human insulin, pen-optimized cartridges gain regulatory and marketing support, further cannibalizing legacy volumes across urban APAC by late decade.
Other drivers and restraints analyzed in the detailed report include:
Sharp Increase in CGM-Guided Basal-Bolus Therapy ScriptsSurge in Low-Dead-Space Safety Syringes for HospitalsEnvironmental Legislation on Single-Use Plastics
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
The 0.5 mL format held 45.67% of Asia-Pacific insulin syringes market share in 2025, reflecting versatility for adult basal-bolus regimens. Asia-Pacific insulin syringes market size for 0.5 mL units is projected to edge from USD 484 million in 2026 to USD 491 million by 2031, growing 0.28% annually. Meanwhile 0.3 mL demand grows 1.22% CAGR, underpinned by gestational and pediatric dosing needs.
Manufacturers invest in tighter tolerance molding and siliconized stoppers to maintain 1 IU accuracy at lower volumes, a critical requirement for neonatal clinics in India and Thailand. Educational outreach via maternity hospitals normalizes smaller barrels, supporting penetration even in cost-sensitive provinces. Although 1 mL syringes remain necessary for insulin-resistant Type 2 cases, their share plateaus amid pen substitution. Specialty "others" formats serve diluted insulin research and retain niche relevance.
The 30G segment commanded 38.35% market share in 2025 and contributes USD 407 million to Asia-Pacific insulin syringes market size, yet 31G & above variants are forecast to climb 1.39% CAGR to 2031. Consumer surveys link thinner needles with 12% higher adherence at 12-month follow-up in Korea.
Investment in micro-taper grinding and electropolishing delivers 15% lower penetration force, matching pen-needle comfort benchmarks. Supply chains shift to higher gauge stainless wire, tightening demand for 28G-29G lines primarily used for viscous insulin analogs. As thinner gauges gain regulatory clearance for sub-cutaneous integrity, hospitals transition bulk contracts to reduce patient refusals and accelerate discharge throughput.
The Asia-Pacific Insulin Syringes Market Report is Segmented by Product Type (0. 3 ML, 0. 5 ML, 1 ML, and Others), Needle Gauge (28G, 29G, and More), Diabetes Type (Type 1, Type 2, and Gestational), End User (Hospitals & Clinics, Home Healthcare, and More), Distribution Channel (Hospital Pharmacies, and More), and Geography (China, India, and More). The Market Forecasts are Provided in Terms of Value (USD).
List of Companies Covered in this Report:
Beckton Dickinson Novo Nordisk Terumo Nipro Owen Mumford Hindustan Syringes & Medical Devices Ltd (HMD) Retractable Technologies Ultimed Allison Medical Inc. Smiths Medical (Tr-K Smiths Group) Ypsomed B. Braun
Additional Benefits:
The market estimate (ME) sheet in Excel format
3 months of analyst support
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing diabetes prevalence & insulin-dependent patients
4.2.2 National reimbursement expansion for pen-averse patients
4.2.3 Sharp increase in CGM-guided basal-bolus therapy scripts
4.2.4 Surge in low-dead-space safety syringes for hospitals
4.2.5 Local contract sterilisation capacity build-out
4.2.6 Generational shift to thinner-gauge, pain-reduction designs
4.3 Market Restraints
4.3.1 Pen-device cannibalisation of syringe volumes
4.3.2 Frequent stock-outs in tier-3 city pharmacies
4.3.3 Environmental legislation on single-use plastics
4.3.4 Patent cliff on BD "Micro-Fine+" design lowering ASPs
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Buyers
4.7.3 Bargaining Power of Suppliers
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD Million)
5.1 By Product Type
5.1.1 0.3 mL
5.1.2 0.5 mL
5.1.3 1 mL
5.1.4 Other Product Types
5.2 By Needle Gauge
5.2.1 28G
5.2.2 29G
5.2.3 30G
5.2.4 31G & Above
5.3 By Diabetes Type
5.3.1 Type 1 Diabetes
5.3.2 Type 2 Diabetes
5.3.3 Gestational Diabetes
5.4 By End User
5.4.1 Hospitals & Clinics
5.4.2 Home Healthcare
5.4.3 Ambulatory Surgical Centres
5.4.4 Other End Users
5.5 By Distribution Channel
5.5.1 Hospital Pharmacies
5.5.2 Retail Pharmacies
5.5.3 Online Pharmacies
5.6 Asia-Pacific
5.6.1 China
5.6.2 India
5.6.3 Japan
5.6.4 South Korea
5.6.5 Australia
5.6.6 Rest of Asia-Pacific
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
6.3.1 Becton, Dickinson and Company (BD)
6.3.2 Novo Nordisk A/S
6.3.3 Terumo Corporation
6.3.4 Nipro Corporation
6.3.5 Owen Mumford Ltd
6.3.6 Hindustan Syringes & Medical Devices Ltd (HMD)
6.3.7 Retractable Technologies Inc.
6.3.8 UltiMed Inc.
6.3.9 Allison Medical Inc.
6.3.10 Smiths Medical (Tr-K Smiths Group)
6.3.11 Ypsomed Holding AG
6.3.12 B. Braun Melsungen AG
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-Need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security